Home » Risk of Glioblastoma Multiforme in Patients Taking Ion Channel Blockers

Risk of Glioblastoma Multiforme in Patients Taking Ion Channel Blockers - TriNetX

Contact Us
Submit RFI/RFP
Trust Center
Ethics Hotline (report a violation)

LIFE SCIENCES
HEALTHCARE
RESOURCES
ABOUT
SIGN IN
- TriNetX LIVE™
- EVIDEX®

Trial Design
Datasets & Analytics
Non-US Oncology
RWE Generation
Drug Safety

Risk of Glioblastoma Multiforme in Patients Taking Ion Channel Blockers

Aug 21, 2023

View

Search for:

SOLUTIONS

Clinical Trial Design & Optimization

Data Sets & Analytics

Non-US Oncology

Insights & Evidence Generation

Drug Safety & Pharmacovigilance

WHO WE SERVE

Healthcare Organizations

RESOURCES

Explore TriNetX RWD

ENTERPRISE

Board of Directors

EMAIL OPT-IN

Get the latest on product updates, services, events, expert insights, and top industry trends.

ABOUT TRINETX, LLC

TriNetX is a global network of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation.

TriNetX, LLC complies with all applicable privacy laws. For more information please visit our Trust Center.

FOLLOW US

LinkedIn

© TriNetX, LLC All Rights Reserved.

Privacy & Cookies

Do not sell or share my personal information